1 week Ago By Defense World Staff
Raymond James Financial Inc. purchased a new position in Tilray Inc (NASDAQ:TLRY – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 192,085 shares of the company’s stock, valued at approximately $255,000.
A number of other institutional investors also recently made changes to their positions in TLRY. Newman Dignan & Sheerar Inc. increased its position in Tilray by 61.
9% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the last quarter.
KBC Group NV grew its stake in shares of Tilray by 75.9% in the fourth quarter. KBC Group NV now owns 38,332 shares of the company’s stock worth $51,000 after acquiring an additional 16,539 shares during the last quarter.
Jones Financial Companies Lllp grew its position in Tilray by 125.7% during the fourth quarter. Jones Financial Companies Lllp now owns 31,725 shares of the company’s stock worth $42,000 after buying an additional 17,670 shares in the last quarter.
Pallas Capital Advisors LLC raised its stake in shares of Tilray by 59.4% in the fourth quarter. Pallas Capital Advisors LLC now owns 50,438 shares of the company’s stock valued at $67,000 after purchasing an additional 18,792 shares in the last quarter.
Finally, Madrona Financial Services LLC increased its stake in Tilray by 40.0% in the fourth quarter. Madrona Financial Services LLC now owns 70,000 shares of the company’s stock valued at $93,000 after acquiring an additional 20,000 shares during the period.
9.35% of the stock is owned by institutional investors and hedge funds. Tilray Price PerformanceNASDAQ:TLRY opened at $0.
51 on Friday. Tilray Inc has a 52-week low of $0.44 and a 52-week high of $2.
52. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.
58 and a current ratio of 2.54. The stock’s 50-day simple moving average is $0.
74 and its 200 day simple moving average is $1.18. The company has a market cap of $473.
89 million, a P/E ratio of -1.68 and a beta of 1.88.
Tilray (NASDAQ:TLRY – Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.
04) by ($0.06). Tilray had a negative net margin of 30.
95% and a negative return on equity of 4.40%. The company had revenue of $185.
78 million during the quarter, compared to analyst estimates of $213.38 million. As a group, sell-side analysts forecast that Tilray Inc will post -0.
2 EPS for the current fiscal year. Analyst Upgrades and DowngradesTLRY has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on shares of Tilray from $2.
00 to $3.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Piper Sandler reduced their target price on shares of Tilray from $2.
00 to $1.00 and set a “neutral” rating on the stock in a research note on Wednesday.Read Our Latest Research Report on TLRYTilray Profile (Free Report)Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis.
The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada. Further ReadingFive stocks we like better than TilrayWhat is the Nasdaq? Complete Overview with HistoryJoby Aviation: Operational Momentum vs.
Market SentimentWhat Are Dividends? Buy the Best Dividend StocksBroadcom’s Big Outperformance Shows Strength Amid Tariff DeclineWhat is a Special Dividend?Carvana: Can Turnaround Strength Outdrive Market Headwinds?.
